Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 Cash, cash equivalents and investments of approximately $188.9M; expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results